Mohit Kaushal Sells 38,433 Shares of Oncology Institute (NASDAQ:TOI) Stock

The Oncology Institute, Inc. (NASDAQ:TOI) Director Mohit Kaushal sold 38,433 shares of the company’s stock in a transaction dated Thursday, April 16th. The stock was sold at an average price of $3.50, for a total transaction of $134,515.50. Following the completion of the sale, the director owned 172,583 shares in the company, valued at approximately $604,040.50. This trade represents a 18.21% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Mohit Kaushal also recently made the following trade(s):

• On Tuesday, April 14th, Mohit Kaushal sold 57,286 shares of Oncology Institute stock. The stock was sold at an average price of $3.50, for a total transaction of $200,501.00.

Oncology Institute Price Performance

Oncology Institute stock traded up $0.11 during midday trading on Thursday, reaching $3.54. 2,190,265 shares of the company traded hands, compared to its average volume of 1,548,966. The firm has a market capitalization of $349.89 million, a price-to-earnings ratio of -6.32 and a beta of 0.17. The business has a 50 day moving average of $2.95 and a two-hundred day moving average of $3.38. The Oncology Institute, Inc. has a 12 month low of $1.91 and a 12 month high of $4.88.

Oncology Institute (NASDAQ:TOI) last announced its earnings results on Thursday, March 12th. The company reported ($0.06) EPS for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.02. The business had revenue of $141.96 million for the quarter, compared to analysts’ expectations of $139.78 million.

Hedge Funds Weigh In On Oncology Institute

A number of large investors have recently added to or reduced their stakes in the stock. Kestra Advisory Services LLC purchased a new position in Oncology Institute during the fourth quarter worth about $31,000. Pekin Hardy Strauss Inc. purchased a new position in Oncology Institute in the 4th quarter valued at $36,000. Cetera Investment Advisers lifted its holdings in Oncology Institute by 35.0% in the second quarter. Cetera Investment Advisers now owns 17,545 shares of the company’s stock valued at $36,000 after acquiring an additional 4,545 shares during the period. State of Wyoming acquired a new position in shares of Oncology Institute during the 2nd quarter worth $37,000. Finally, R Squared Ltd acquired a new position in Oncology Institute in the 4th quarter valued at about $41,000. 36.86% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

TOI has been the subject of several recent research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Oncology Institute in a report on Wednesday, January 21st. Needham & Company LLC reaffirmed a “buy” rating and issued a $5.00 price objective on shares of Oncology Institute in a research report on Monday, March 9th. B. Riley Financial lifted their price objective on shares of Oncology Institute from $6.00 to $8.00 and gave the stock a “buy” rating in a research report on Friday, March 13th. Finally, BTIG Research reaffirmed a “buy” rating and issued a $7.00 price objective on shares of Oncology Institute in a research report on Monday, March 9th. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $7.00.

About Oncology Institute

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies.